SIGLEC7 and glioma: Additionally, in Cox regression analysis, we included SIGLEC7 expression levels, WHO grade, age at diagnosis, IDH status, 1p/19q co-deletion status, and MGMT promoter methylation status as factors in both univariate and multivariate survival analyses, further confirming the significant prognostic impact of SIGLEC7 expression levels in glioma patients (Figures 8C, D).